$STLN Cashflow Statement | Understand Stock

$STLN

$6.59 +$0.30 (4.77%) Close

$STLN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to cash and cash equivalents used in operating activities:
Depreciation and amortization
Amortization of debt issuance costs and debt discount
Impairment loss
Goodwill impairment charges
Write-off of assets from clinical trials segment
Share-based compensation
Change in fair value of liability classified warrants
Change in fair value of liability classified earnouts
Change in fair value of liability classified conversion option derivatives
Unrealized (gain) loss on investments
Accretion of discount on investment securities
Deferred taxes
Gain on loan forgiveness
Bad debt expense
Loss on disposal of property and equipment
Changes in operating assets and liabilities:
Accounts receivable
Inventories
Other receivables
Prepaid expenses
Operating lease right-of-use assets
Other assets
Accrued expenses and other current liabilities
Income taxes payable
Accounts payable
Change in operating leases
Other non-current liabilities

Net cash and cash equivalents used in operating activities
Cash flows from investing activities:
Purchases of property and equipment
Purchases of intangible asset in practice acquisitions
Cash paid for practice acquisitions, net
Issuance of notes receivable
Purchases of marketable securities/investments
Proceeds from asset disposition
Sales of marketable securities/investments
Net cash and cash equivalents provided by (used in) investing activities

Cash flows from financing activities:
Transaction costs
Proceeds from issuance of long-term debt
Transactions costs related to issuance of long-term debt
Proceeds from financing of insurance payments
Proceeds from private placement, net of offering costs
Proceeds from at-the-market offering, net of offering costs
Proceeds from employee stock purchase plan
Payments made for financing of insurance payments
Payment of deferred consideration liability for acquisition
Principal payments on long-term debt
Principal payments on financing leases
Deferred offering costs
Common stock repurchase
Common stock issued for warrants exercised
Common stock issued for options exercised
Taxes for common stock net settled
Issuance of Legacy TOI preferred stock
Net cash and cash equivalents provided by (used in) financing activities

Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information:
Interest and principal forgiven from Paycheck Protection Program loans
Cash paid for:
Income taxes
Interest

Supplemental disclosure of noncash investing and financing activities:
Reclassification of public warrant derivative liability related to the recapitalization transaction into equity
Fair value of net assets acquired as part of practice acquisitions, less cash
Fair value of assets acquired as part of acquisition (except for cash and goodwill)
Deferred consideration as part of practice acquisitions
Discount on senior secured convertible note
Principal exchange of convertible note for preferred stock
Right-of-use assets in connection with operation lease modifications
Financed insurance premiums
Purchases of property and equipment included in accounts payable

Comments